StreetInsider.com News Articles

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, presented multiple clinical and preclinical results of its innovative metabolic and obesity pipeline at the 2026 American Diabetes Association's^® (ADA) Scientific Sessions. This includes three clinical oral presentations of mazdutide (GCG/GLP-1 dual agonist) across adults with type 2 diabetes and obesity, adults with

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

Mon, 08 Jun 2026 04:30:00 -0400

Innovent submits gastric cancer drug for China regulatory review

Thu, 04 Jun 2026 04:35:21 -0400

Innovent Biologics Inc. (HKEX: 01801) announced that its experimental cancer drug arcotatug tavatecan met the primary endpoint in a Phase 3 clinical trial for advanced gastric cancer treatment. The company has submitted a new drug application to China's National Medical Products Administration, which has been accepted with priority review status.

The international Phase 3 study, called G-HOPE-001, evaluated the drug in patients with previously treated, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who received at least two prior systemic therapies. The trial was conducted in China and Japan, comparing the drug against investigator-selected therapy.

Arcotatug tavatecan is an antibody-drug

Innovent submits gastric cancer drug for China regulatory review

Thu, 04 Jun 2026 04:35:21 -0400

Arcotatug tavatecan is an antibody-drug

Innovent submits gastric cancer drug for China regulatory review

Thu, 04 Jun 2026 04:35:21 -0400

Arcotatug tavatecan is an antibody-drug

Innovent submits gastric cancer drug for China regulatory review

Thu, 04 Jun 2026 04:35:21 -0400

Arcotatug tavatecan is an antibody-drug

Innovent submits gastric cancer drug for China regulatory review

Thu, 04 Jun 2026 04:35:21 -0400

Arcotatug tavatecan is an antibody-drug

Innovent submits gastric cancer drug for China regulatory review

Thu, 04 Jun 2026 04:35:21 -0400

Arcotatug tavatecan is an antibody-drug

Innovent submits gastric cancer drug for China regulatory review

Thu, 04 Jun 2026 04:35:21 -0400

Arcotatug tavatecan is an antibody-drug

Innovent submits gastric cancer drug for China regulatory review

Thu, 04 Jun 2026 04:35:21 -0400

Arcotatug tavatecan is an antibody-drug

Innovent submits gastric cancer drug for China regulatory review

Thu, 04 Jun 2026 04:35:21 -0400

Arcotatug tavatecan is an antibody-drug

World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer an

Thu, 04 Jun 2026 04:35:00 -0400

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the international multi-center Phase 3 clinical study (G-HOPE-001, NCT06238843) of arcotatug tavatecan (IBI343; Takeda R&D code: TAK-921, an innovative TOPO1i CLDN18.2 ADC) has completed the per-protocol first interim analysis and reached the primary endpoint. Arcotatug tavatecan demonstrated excellent efficacy and a tolerable safety profile

World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer an

Thu, 04 Jun 2026 04:35:00 -0400